v3.22.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Revenue $ 189
Cost of revenue 369
Gross profit (loss) (180)
Operating expenses:    
Sales and marketing 3,925 1,387
General and administrative 9,423 3,375
Research and development 5,932 3,315
Total operating expenses 19,280 8,077
Loss from operations (19,460) (8,077)
Other income (expense):    
Change in fair value - contingent consideration payable (173)
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note 1,682
Debt extinguishments loss - Senior Secured Convertible Notes (3,715)
Other income (expense), net (173) (2,033)
Loss before provision for income tax (19,633) (10,110)
Provision for income taxes
Net loss before noncontrolling interests (19,633) (10,110)
Net loss attributable to the noncontrolling interests 2,761 679
Net loss attributable to PAVmed Inc. (16,872) (9,431)
Less: Series B Convertible Preferred Stock dividends earned (68) (75)
Net loss attributable to PAVmed Inc. common stockholders $ (16,940) $ (9,506)
Per share information:    
Net loss per share attributable to PAVmed Inc. - basic and diluted $ (0.20) $ (0.13)
Net loss per share attributable to PAVmed Inc. common stockholders – basic and diluted $ (0.20) $ (0.13)
Weighted average common shares outstanding, basic and diluted 86,336,427 73,954,126

Source